Categories
- Global News Feed
- Uncategorized
- Alabama Stem Cells
- Alaska Stem Cells
- Arkansas Stem Cells
- Arizona Stem Cells
- California Stem Cells
- Colorado Stem Cells
- Connecticut Stem Cells
- Delaware Stem Cells
- Florida Stem Cells
- Georgia Stem Cells
- Hawaii Stem Cells
- Idaho Stem Cells
- Illinois Stem Cells
- Indiana Stem Cells
- Iowa Stem Cells
- Kansas Stem Cells
- Kentucky Stem Cells
- Louisiana Stem Cells
- Maine Stem Cells
- Maryland Stem Cells
- Massachusetts Stem Cells
- Michigan Stem Cells
- Minnesota Stem Cells
- Mississippi Stem Cells
- Missouri Stem Cells
- Montana Stem Cells
- Nebraska Stem Cells
- New Hampshire Stem Cells
- New Jersey Stem Cells
- New Mexico Stem Cells
- New York Stem Cells
- Nevada Stem Cells
- North Carolina Stem Cells
- North Dakota Stem Cells
- Oklahoma Stem Cells
- Ohio Stem Cells
- Oregon Stem Cells
- Pennsylvania Stem Cells
- Rhode Island Stem Cells
- South Carolina Stem Cells
- South Dakota Stem Cells
- Tennessee Stem Cells
- Texas Stem Cells
- Utah Stem Cells
- Vermont Stem Cells
- Virginia Stem Cells
- Washington Stem Cells
- West Virginia Stem Cells
- Wisconsin Stem Cells
- Wyoming Stem Cells
- Biotechnology
- Cell Medicine
- Cell Therapy
- Diabetes
- Epigenetics
- Gene therapy
- Genetics
- Genetic Engineering
- Genetic medicine
- HCG Diet
- Hormone Replacement Therapy
- Human Genetics
- Integrative Medicine
- Molecular Genetics
- Molecular Medicine
- Nano medicine
- Preventative Medicine
- Regenerative Medicine
- Stem Cells
- Stell Cell Genetics
- Stem Cell Research
- Stem Cell Treatments
- Stem Cell Therapy
- Stem Cell Videos
- Testosterone Replacement Therapy
- Testosterone Shots
- Transhumanism
- Transhumanist
Archives
Recommended Sites
Category Archives: Global News Feed
Sorrento Announces That Sorrento Mexico Has Sold Out of One Million COVISTIX Tests Last Week in Mexico
Posted: January 20, 2022 at 2:09 am
SAN DIEGO, Jan. 19, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") and Sorrento Mexico today announced that approximately 1,000,000 COVISTIX tests were distributed last week in Mexico. Orders are increasing daily as pent-up demand is high for a sensitive and convenient test that is capable of accurately detecting all of the current variants of the SARS-CoV-2 virus, including the dominant Omicron variant. Millions of additional COVISTIX tests are scheduled to be delivered to Mexico, with tens of millions more being manufactured to support the increasing demand for COVISTIX worldwide. “We believe there is a significant unmet need for a sensitive and rapid antigen test which detects Omicron with high sensitivity even for asymptomatic patients,” stated Dr. Henry Ji, Chairman and CEO of Sorrento Therapeutics.
Read this article:
Sorrento Announces That Sorrento Mexico Has Sold Out of One Million COVISTIX Tests Last Week in Mexico
Posted in Global News Feed
Comments Off on Sorrento Announces That Sorrento Mexico Has Sold Out of One Million COVISTIX Tests Last Week in Mexico
The Connection Study continues after pre-scheduled Data Monitoring Committee (DMC) review
Posted: January 20, 2022 at 2:09 am
On September 30, 2021 Infant Bacterial Therapeutics (IBT) announced that the company had reached a key milestone in the development of IBP-9414, after having recruited 600 premature infants to The Connection Study. The DMC has completed its pre-scheduled safety analysis without any concerns. At the same time a futility analysis was performed. Based on DMC recommendations and futility outcome, IBT is continuing the recruitment to the study as planned.
Read more:
The Connection Study continues after pre-scheduled Data Monitoring Committee (DMC) review
Posted in Global News Feed
Comments Off on The Connection Study continues after pre-scheduled Data Monitoring Committee (DMC) review
HUTCHMED Initiates a Phase I Trial of HMPL-653 in Patients with Advanced Malignant Solid Tumors and TGCT in China
Posted: January 20, 2022 at 2:09 am
HONG KONG, SHANGHAI and FLORHAM PARK, N.J., Jan. 19, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated a Phase I trial in China of HMPL-653, an investigational novel, highly selective, and potent colony-stimulating factor 1 receptor (“CSF-1R”) inhibitor. The first patient received their first dose on January 18, 2022.
Posted in Global News Feed
Comments Off on HUTCHMED Initiates a Phase I Trial of HMPL-653 in Patients with Advanced Malignant Solid Tumors and TGCT in China
Idorsia receives Japanese PMDA approval of PIVLAZ (clazosentan sodium) 150 mg
Posted: January 20, 2022 at 2:09 am
Ad hoc announcement pursuant to Art. 53 LR
See the original post:
Idorsia receives Japanese PMDA approval of PIVLAZ (clazosentan sodium) 150 mg
Posted in Global News Feed
Comments Off on Idorsia receives Japanese PMDA approval of PIVLAZ (clazosentan sodium) 150 mg
The Lancet Neurology reports impact of daridorexant on both nighttime symptoms and daytime functioning in adults with insomnia
Posted: January 20, 2022 at 2:09 am
The Lancet Neurology reports impact of daridorexant on both nighttime symptoms and daytime functioning in adults with insomnia
See the original post:
The Lancet Neurology reports impact of daridorexant on both nighttime symptoms and daytime functioning in adults with insomnia
Posted in Global News Feed
Comments Off on The Lancet Neurology reports impact of daridorexant on both nighttime symptoms and daytime functioning in adults with insomnia
Updated: Adaptive Biotechnologies to Present Virtually at the 40th Annual J.P. Morgan Healthcare Conference
Posted: January 5, 2022 at 2:30 am
SEATTLE, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming 40th Annual J.P. Morgan Healthcare Conference.
See more here:
Updated: Adaptive Biotechnologies to Present Virtually at the 40th Annual J.P. Morgan Healthcare Conference
Posted in Global News Feed
Comments Off on Updated: Adaptive Biotechnologies to Present Virtually at the 40th Annual J.P. Morgan Healthcare Conference
Annexon Biosciences Reports Promising Interim Phase 2 Data Showing Improvement in Clinical Measures with ANX005 in Huntington’s Disease Following…
Posted: January 5, 2022 at 2:30 am
ANX005 Has Been Generally Well-Tolerated and Has Shown Full Target Engagement of C1q in the CSF
Originally posted here:
Annexon Biosciences Reports Promising Interim Phase 2 Data Showing Improvement in Clinical Measures with ANX005 in Huntington’s Disease Following...
Posted in Global News Feed
Comments Off on Annexon Biosciences Reports Promising Interim Phase 2 Data Showing Improvement in Clinical Measures with ANX005 in Huntington’s Disease Following…
Caladrius Biosciences Announces Participation in Upcoming Conferences in January 2022
Posted: January 5, 2022 at 2:30 am
BASKING RIDGE, N.J., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies designed to treat or reverse disease, today announced its participation in several industry and investor events. All presentations are pre-recorded and available on-demand through the online conference platforms.
More here:
Caladrius Biosciences Announces Participation in Upcoming Conferences in January 2022
Posted in Global News Feed
Comments Off on Caladrius Biosciences Announces Participation in Upcoming Conferences in January 2022
Akero Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
Posted: January 5, 2022 at 2:30 am
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will present at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11 at 10:30 a.m. E.T.
Read the original post:
Akero Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
Posted in Global News Feed
Comments Off on Akero Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
PacBio to Present at Upcoming Investor Conference
Posted: January 5, 2022 at 2:30 am
MENLO PARK, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- PacBio announced today that its executives will be speaking virtually at the following investor conference:
Read more from the original source:
PacBio to Present at Upcoming Investor Conference
Posted in Global News Feed
Comments Off on PacBio to Present at Upcoming Investor Conference